Next Article in Journal
Pharmacogene Variants Associated with Liver Transplant in a Twelve-Year Clinical Follow-Up
Next Article in Special Issue
Photosensitive EGFR-Targeted Nanocarriers for Combined Photodynamic and Local Chemotherapy
Previous Article in Journal
Cytotoxicity and Apoptosis Induction of 6,7-Dehydroroyleanone from Taiwania cryptomerioides Bark Essential Oil in Hepatocellular Carcinoma Cells
Previous Article in Special Issue
EGFR-Targeted Photodynamic Therapy
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 14
Issue 2
10.3390/pharmaceutics14020353
Review Report
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Therapeutic Options for Recurrent Glioblastoma—Efficacy of Talaporfin Sodium Mediated Photodynamic Therapy

Pharmaceutics 2022, 14(2), 353; https://doi.org/10.3390/pharmaceutics14020353
by Tatsuya Kobayashi 1, Masayuki Nitta 1,2,*, Kazuhide Shimizu 3,4, Taiichi Saito 1,2, Shunsuke Tsuzuki 1, Atsushi Fukui 1, Shunichi Koriyama 1, Atsushi Kuwano 1, Takashi Komori 5, Kenta Masui 6, Taketoshi Maehara 4, Takakazu Kawamata 1 and Yoshihiro Muragaki 1,2
Reviewer 1: Anonymous
Pharmaceutics 2022, 14(2), 353; https://doi.org/10.3390/pharmaceutics14020353
Submission received: 22 December 2021 / Revised: 28 January 2022 / Accepted: 1 February 2022 / Published: 2 February 2022
(This article belongs to the Special Issue Drug Delivery in Photodynamic Therapy (PDT))

Round 1

Reviewer 1 Report

In the manuscript entitled “Therapeutic Options for Recurrent Glioblastoma - Efficacy of Talaporfin Sodium mediated Photodynamic Therapy”, Tatsuya et al. retrospectively evaluated the efficacy of talaporfin sodium (TS) mediated photodynamic therapy (PDT) as a treatment for recurrent GBM. The manuscript compares the prognostic effects of different treatments for patients with recurrent GBM. The results suggest that additional TS-PDT treatment for recurrent GBM could have potential survival benefits. The comments are given as follows.

 

  1. In the chapter 3.2, several complications occurred in the PDT group but none in the control group. Please explain this and give the reasons for the reduction of the complications.
  2. ROS produced by PDT could destroy various cellular organelles and tumor blood vessels, leading to the destruction of tumors. However, this conclusion has not been confirmed in GBM. The author should provide more direct evidence that TS-mediated PDT can also play a similar role in GBM.
  3. The absorption rate of TS has a great influence on the effect of treatment. However, only the GBM and LGG groups are compared in the manuscript. The author should conduct a more detailed analysis of the influencing factors of TS absorption rate and the relationship between absorption rate and PFS and OS.

Author Response

Thank you for your review and comments.

Please see the attachment.

 

Author Response File: Author Response.docx

Reviewer 2 Report

The methodology used to analyze TS accumulation in GBM and normal tissue is referenced but I recommend to add a brief description (additional to the already mentioned).

Also, in Figure 3, please check if is there a mistake in the nomenclature of images. I observe greater red fluorescence in normal tissue than in GBM tissue, and authors claim the opposite in the text (page 7 of 13, line 219-220).

 

Author Response

Thank you for your review and comments.

Please see the attachment.

Author Response File: Author Response.docx

Back to TopTop